Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
AMI to become part of Enpro’s Sealing Technologies Segment
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
AHHL is primarily engaged in nursing care, in home primary care, physiotherapy at home, sample collection, post-operative/post-surgical care
The plant is yet to start commercial operations
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Subscribe To Our Newsletter & Stay Updated
